Methods and compositions for identifying epitopes
The system of engineered APCs with exogenous nucleic acids and molecular reporters effectively identifies and recovers T cell-specific antigens, addressing the challenges of rare and complex antigen interactions, enhancing the discovery and recovery of relevant antigens.
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- THE BRIGHAM & WOMEN S HOSPITAL INC
- Filing Date
- 2026-07-07
- Publication Date
- 2026-07-23
AI Technical Summary
Identifying target antigens specific to T cells, such as cytotoxic T cells, is challenging due to the rarity and complexity of their interactions with antigen-presenting cells, leading to inefficient and biased discovery of antigens that may not be functionally displayed in vivo.
A system comprising antigen-presenting cells (APCs) engineered with exogenous nucleic acids encoding candidate antigens, a molecular reporter of Granzyme B activity, and an inhibitor of CAD-mediated DNA degradation, allowing for high-throughput detection and recovery of antigens recognized by cytotoxic lymphocytes.
Enables sensitive and robust identification of antigens recognized by cytotoxic T cells and NK cells, overcoming low throughput and bias in antigen discovery, and facilitating the recovery of presenting APCs and antigens driving immune responses.
Smart Images

Figure 00000002_0000 
Figure 00000073_0000 
Figure 00000074_0000